Financial Performance - For the fiscal year ending December 31, 2025, total revenue was SGD 46,276,000, a decrease of 7.8% from SGD 50,241,000 in 2024[4] - Gross profit for the fiscal year was SGD 7,189,000, down 37.5% from SGD 11,477,000 in the previous year[4] - The company reported a pre-tax loss of SGD 17,162,000, slightly improved from a loss of SGD 18,227,000 in 2024[4] - The total comprehensive loss for the year was SGD 16,448,000, compared to SGD 19,111,000 in 2024, indicating a reduction of 13.9%[5] - The company reported a total loss of SGD 17,395,000 for 2025, slightly improved from a loss of SGD 18,255,000 in 2024[12] - The group recorded a loss of SGD 17.4 million in FY2025, compared to a loss of SGD 18.3 million in FY2024, primarily due to decreased gross profit offset by reduced administrative expenses[34] Revenue and Growth - Revenue from customer contracts in China is expected to increase to SGD 29,989,000 in 2025 from SGD 25,927,000 in 2024, reflecting a growth of about 15.8%[11] - Sales from minimally invasive surgical solutions and related medical products increased by SGD 4.037 million to SGD 29.964 million in FY2025[27] - Revenue from minimally invasive surgical solutions and related services increased from SGD 25.9 million in FY2024 to SGD 30.0 million in FY2025, primarily due to growth in the Chinese market[28] - Revenue from labor dispatch and supporting services decreased from SGD 15.1 million in FY2024 to SGD 12.7 million in FY2025, attributed to a downturn in Singapore's dispatch and supporting services[28] Assets and Liabilities - Total assets increased to SGD 88,834,000 in 2025, up from SGD 58,867,000 in 2024, representing a growth of 50.9%[6] - Total liabilities increased to SGD 36,872,000, up from SGD 26,088,000, which is a rise of 41.2%[7] - The company’s equity attributable to owners increased to SGD 51,288,000 from SGD 31,806,000, a growth of 61.2%[6] - As of December 31, 2025, the group's total borrowings and lease liabilities were SGD 14.9 million, a slight increase from SGD 14.5 million in 2024, primarily due to loans from the parent company for operational purposes[44] Cash Flow and Financing - Cash and cash equivalents rose significantly to SGD 35,588,000 from SGD 10,446,000, marking an increase of 240.5%[6] - The group’s cash and cash equivalents as of December 31, 2025, totaled SGD 35.6 million, with 93% held in RMB, 1% in HKD, and 6% in SGD[45] - The company incurred total financing costs of SGD 675,000 in 2025, down from SGD 773,000 in 2024, a reduction of about 12.7%[12] - Financing costs slightly decreased by SGD 0.1 million in FY2025[32] Stock Options and Corporate Governance - The company has adopted a stock option plan approved by shareholders on December 29, 2023, allowing eligible participants to acquire ownership interests in the company[62] - A total of 128,603,750 stock options were granted on January 9, 2024, with an exercise price of HKD 2.54 per share, based on the highest of the closing price on the grant date or the average closing price over the previous five trading days[68] - The stock option plan has a maximum duration of 10 years, with a cap on the total number of shares that can be issued under the plan not exceeding 10% of the issued shares as of the special meeting date[64] - The company has adopted the corporate governance code and complied with all applicable provisions during the year[80] Risk Management - The company has implemented policies to minimize credit risk, including setting credit limits and conducting credit assessments before accepting new customers[57] - Trade receivables are evaluated at each reporting period to ensure adequate impairment losses are recognized, reflecting a significant reduction in credit risk[58] - The company maintains sufficient cash and cash equivalents to manage liquidity risk and reduce cash flow volatility[59] - The company faces fair value risk from financial assets and liabilities measured at fair value on a recurring and non-recurring basis[60] Future Plans and Investments - The group plans to allocate resources towards providing minimally invasive surgical solutions and related services, enhancing R&D capabilities, and expanding distribution networks[23] - The group plans to utilize the proceeds from the August 2025 placement, totaling HKD 161 million, for potential acquisitions in the healthcare sector and R&D expenses, with all funds expected to be used by the end of 2026[43] - The intended use of proceeds includes HKD 69 million for expanding the medical industry business, HKD 15 million for labor dispatch and supporting services, and HKD 15 million for general working capital[42] Employee and Operational Data - The group employed 485 staff members as of December 31, 2025, with total employee costs amounting to SGD 22.5 million for the fiscal year 2025[53] - The audit committee has reviewed the annual audited results and confirmed that the financial statements are prepared in accordance with applicable accounting standards and regulations[82] Miscellaneous - The company has not declared or paid any dividends for the years ending December 31, 2025, and 2024[17] - The group has no significant contingent liabilities as of December 31, 2025[48] - The company has no significant off-balance sheet transactions as of December 31, 2025[52] - The company expresses gratitude to all customers, management, employees, business partners, and shareholders for their continued support[86]
今海医疗科技(02225) - 2025 - 年度业绩